Greenwich Lifesciences Inc (GLSI) - Total Assets
Based on the latest financial reports, Greenwich Lifesciences Inc (GLSI) holds total assets worth $10.51 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore GLSI current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Greenwich Lifesciences Inc - Total Assets Trend (2017–2025)
This chart illustrates how Greenwich Lifesciences Inc's total assets have evolved over time, based on quarterly financial data.
Greenwich Lifesciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Greenwich Lifesciences Inc's total assets of $10.51 Million consist of 0.0% current assets and 0.0% non-current assets. Also see GLSI stock market capitalisation for the company's overall valuation and market capitalisation.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Greenwich Lifesciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Greenwich Lifesciences Inc (GLSI) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Greenwich Lifesciences Inc's current assets represent 0.0% of total assets in 2025, a decrease from 0.2% in 2017.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2025, down from 0.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Greenwich Lifesciences Inc Competitors by Total Assets
Key competitors of Greenwich Lifesciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
BRITANNIA LIFE SCIENCES
F:L020
|
Germany | €22.06 Million |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
ABCELLERA BIOLOGICS
F:8QQ
|
Germany | €1.36 Billion |
Greenwich Lifesciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.01 | 1.91 | 45.66 |
| Quick Ratio | 2.01 | 1.91 | 45.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.27 Million | $1.31 Million | $29.15 Million |
Greenwich Lifesciences Inc - Advanced Valuation Insights
This section examines the relationship between Greenwich Lifesciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 61.61 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -264.6% |
| Total Assets | $-6.74 Million |
| Market Capitalization | $227.51 Million USD |
Valuation Analysis
Below Book Valuation: The market values Greenwich Lifesciences Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Greenwich Lifesciences Inc's assets decreased by 264.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Greenwich Lifesciences Inc (2017–2025)
The table below shows the annual total assets of Greenwich Lifesciences Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $-6.74 Million | -264.61% |
| 2024-12-31 | $4.09 Million | -41.47% |
| 2023-12-31 | $6.99 Million | -48.10% |
| 2022-12-31 | $13.48 Million | -50.48% |
| 2021-12-31 | $27.22 Million | -5.09% |
| 2020-12-31 | $28.68 Million | +107419.79% |
| 2019-12-31 | $26.67K | -75.43% |
| 2018-12-31 | $108.55K | +300.48% |
| 2017-12-31 | $27.10K | -- |
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Ph… Read more